Haixi Bio Completes Tens-of-Millions RMB Series A Financing to Accelerate Blood Diagnostic Kit Development and Global Expansion

VCBeat has learned that Wuhan Healthy Biotechnology Co., Ltd. (“Healthy Bio”) recently announced the completion of its Series A financing round, amounting to tens of millions of yuan.

This round of financing was exclusively invested by the Ruijiang Kangsheng Phase II Fund. The funds will be primarily used to accelerate the translation of the company’s R&D achievements in hematology-specific clinical testing into standardized in vitro diagnostic (IVD) kits, as well as to support Healthy Biotechnology’s globalization strategy.

Wuhan Healthy Biotechnology Co., Ltd. was established in February 2019 as a spin-off from KingMed Diagnostics, focusing on the R&D, manufacturing, sales, and services of specialized diagnostic products and biomedical research reagents and equipment for hematologic diseases. The company boasts an R&D center spanning over 2,000 square meters and a production base exceeding 5,000 square meters, located respectively in Wuhan Optics Valley Bio-city and Ezhou Gedian Bio-city. To date, the company has developed and manufactured more than 100 kit products on PCR, qPCR, Sanger sequencing, and NGS technology platforms, among which 34 have obtained CE certification. Its product portfolio covers gene testing solutions for myeloid hematologic malignancies, lymphoid hematologic malignancies, hereditary hematologic disorders, and transplantation-related indications, providing comprehensive support across all stages including differential diagnosis, genotyping, prognostic stratification, targeted therapy, and efficacy monitoring.

Selected Registered Kits from Healthy Biotechnology

Leveraging Kindstar Global’s 20 years of profound expertise and unique advantages in the field of clinical hematology testing, Healthy Biotech has successfully commercialized over 104 reagents, 34 of which have obtained CE certification. This fund investment will focus on accelerating the transformation of Kindstar Global’s clinical hematology testing technologies into standardized in vitro diagnostic (IVD) products and advancing their registration processes with relevant regulatory authorities.

Dr. Li Xiaoqing, Chief Scientist of the Company, stated: “We sincerely appreciate Ruijiang Investment’s follow-on investment in Healthy Biotechnology. Healthy Biotechnology is committed to providing precise and reliable diagnostic reagents in the field of specialized testing, while also supplying high-standard research reagents and exceptional services to biomedical researchers. This financing round not only signifies capital market recognition of Healthy Biotechnology’s technology and market potential but will also empower the company to accelerate product innovation and market expansion. The injected funds will be directly allocated to strengthening R&D efforts, ensuring rapid regulatory approval and commercialization of products, thereby driving the optimization and upgrading of the company’s existing product portfolio.”

Zhao Jinqiang, Chairman of Ruijiang Investment, stated that the continued increase in investment in Healthy Biotechnology upholds the fund’s philosophy of empowering clinical medicine and the health industry through investments in innovative technologies, alleviating the suffering caused by diseases for patients, and further benefiting the public. This additional investment in Healthy Biotechnology aims to strengthen the R&D and promotion of the IVD transformation of blood testing LDT products and related instruments and equipment, while also supporting Healthy Biotechnology’s globalization strategy. This investment holds significant importance for clinical medicine and demonstrates Ruijiang Investment’s commitment to its investment philosophy of discovering and creating value, partnering with exceptional entrepreneurs, and unlocking infinite possibilities.

Ruijiang Investment was established in 2012, with its headquarters in Wuhan and branches and teams in Beijing, Shanghai, Chengdu, and Shenzhen. The company’s vision is to meet people’s needs for a better life through high-quality financial services and products. Its core business covers the management of equity investment funds and industrial investment funds. Discovering and creating value, and partnering with outstanding entrepreneurs, has always been our consistent philosophy. The company’s founder graduated from the University of Chicago, and its management and investment teams are composed of seasoned investment professionals with an international perspective. Its growth-stage equity investment funds focus on the healthcare, hard technology, environmental protection, and education sectors. The company currently manages eight equity investment funds, with past limited partners (LPs) including funds of funds, family offices, and listed companies.